BRCA1 and breast adenocarcinoma: AP-1 significantly synergised doxorubicin against the metastatic MCF7 breast adenocarcinoma cells via TP53/ATM-mediated homologous recombination for the DNA DSBs repair through BRCA1 upregulation and RIF1 downregulation.